TORONTO, March 7,
2022 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or
the "Company") (TSXV: KHRN)(OTCQX: KHRNF)(Frankfurt: A2JMZC), a medical cannabis leader
with core operations in Latin
America and Europe, is
scheduled to participate in the following virtual and in-person
conferences in March 2022:
Q1 2022 VIRTUAL INVESTOR SUMMIT
March 8 -10, 2022
Khiron Presentation: Tuesday, March
8th at 9:30 a.m. ET
Webcast:
https://us06web.zoom.us/webinar/register/WN_8jJhKli3RlGaM9H1qZ_xSA
OTC LIFE SCIENCES VIRTUAL INVESTOR
CONFERENCE
March
10, 2022
Khiron Presentation: Thursday, March
10th at 11:30 a.m. ET
Webcast: https://bit.ly/3LRhCdu
34th ANNUAL ROTH CAPITAL PARTNERS
CONFERENCE
Dana
Point, California
March 13-15, 2022
Alvaro Torres, CEO and Franziska
Katterbach, Europe President attending 1x1 Meetings
Webcast: https://wsw.com/webcast/roth43/khrn/1834188
Roth Capital hosted events are intended for prospective and
existing Roth clients and management participants. To learn more
and submit a registration request, visit
https://ibn.fm/ROTH2022Registration
For more information about the conferences or to schedule a
1-on-1 meeting with the Khiron management, please contact the
company's investor relations team at investors@khiron.ca
About Khiron Life Sciences Corp.
Khiron is a
leading vertically integrated international medical cannabis
company with core operations in Latin
America and Europe.
Leveraging wholly-owned medical health clinics and proprietary
telemedicine platforms, Khiron combines a patient-oriented
approach, physician education programs, scientific expertise,
product innovation, and agricultural infrastructure to drive
prescriptions and brand loyalty with patients worldwide. The
Company has a sales presence in Colombia, Peru, Germany, UK, and Brazil and is positioned to commence sales in
Mexico. The Company is led by
Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced and
diverse executive team and Board of Directors.
Visit Khiron online at investors.khiron.ca
Linkedin
https://www.linkedin.com/company/khiron-life-sciences-corp/
Cautionary Notes
Forward-Looking Statements
This press release may contain certain "forward-looking
information" and "forward-looking statements" within the meaning of
applicable securities legislation. All information contained herein
that is not historical in nature may constitute forward-looking
information. Khiron undertakes no obligation to comment on
analyses, expectations or statements made by third-parties in
respect of Khiron, its securities, or financial or operating
results (as applicable). Although Khiron believes that the
expectations reflected in forward-looking statements in this press
release are reasonable, such forward-looking statement has been
based on expectations, factors and assumptions concerning future
events which may prove to be inaccurate and are subject to numerous
risks and uncertainties, certain of which are beyond Khiron's
control, including the risk factors discussed in Khiron's Annual
Information Form which is available on Khiron's SEDAR profile at
www.sedar.com. The forward-looking information contained in this
press release is expressly qualified by this cautionary statement
and is made as of the date hereof. Khiron disclaims any intention
and has no obligation or responsibility, except as required by law,
to update or revise any forward-looking information, whether as a
result of new information, future events or otherwise.
Neither the TSXV nor its Regulation Services Provider (as that
term is defined in the policies of the TSXV) accepts responsibility
for the adequacy or accuracy of this press release.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/khiron-life-sciences-to-present-at-upcoming-march-investor-conferences-301496909.html
SOURCE Khiron Life Sciences Corp.